Two cancer immunotherapy makers face different situations in reimbursement talks

18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...

Read more →

Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund

17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...

Read more →

Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer

16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...

Read more →

Seattle Genetics and Astellas announce submission of biologics license application to FDA for enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer

16 July 2019 - Submission based on pivotal Phase 2 trial results recently presented at Annual Meeting of American Society of ...

Read more →

Protecting PHARMAC and cancer treatment

13 July 2019 - The "postcode lottery", delays and other failings for cancer treatment need to be addressed. ...

Read more →

Janssen submits application to U.S. FDA seeking approval of new Darzalex (daratumumab) subcutaneous formulation

12 July 2019 - Submission inclusive of data from Phase 3 COLUMBA study presented at ASCO. ...

Read more →

Improving affordability of new essential cancer medicines

11 July 2019 - Effective cancer care requires investment in health infrastructure, a trained health workforce, and quality-assured, affordable medicines within ...

Read more →

Proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas

11 July 2019 - PHARMAC is seeking feedback on proposals for funding in the immunosuppressant, oncology, vasodilator and smoking cessation ...

Read more →

Health Canada approves Pomalyst-based triplet combination for patients with multiple myeloma

10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple ...

Read more →

Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...

Read more →

FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma

10 July 2019 - The U.S. FDA has accepted for review the biologics license application for isatuximab for the treatment ...

Read more →

Cellectar receives FDA fast track designation for CLR 131 in diffuse large B-cell lymphoma

9 July 2019 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in relapsed ...

Read more →

FDA accepts Merck’s supplemental biologics license applications for Keytruda (pembrolizumab) six-week dosing schedule for melanoma and multiple other indications

9 July 2019 - Merck today announced that the U.S. FDA has accepted for review six supplemental biologics license applications to ...

Read more →

The fragility of phase 3 trials supporting FDA approved anti-cancer medicines: a retrospective analysis

8 July 2019 - The fragility index of trial results—ie, the minimum number of changes from non-events to events resulting in ...

Read more →

Breast cancer specialists throw their weight behind long-running fight for increased Government drug funding

9 July 2019 - Several petitions, two marches on Parliament and countless emotive pleas have been fruitless in a long-running ...

Read more →